Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Cost of Revenue data on file, last reported at $696.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 11.9% year-over-year to $696.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 billion (down 39.3% YoY), and the FY2025 full-year result was $8.3 billion, down 1.9% from the prior year.
• Cost of Revenue for Q1 2026 stood at $696.0 million, down from $2.1 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $6.6 billion in Q4 2024 and bottomed at $539.0 million in Q3 2022.
• A 5-year average of $1.9 billion and a median of $2.1 billion in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue plunged 71.13% in 2023 and soared 980.33% in 2024, its largest moves.
• Tracing TEVA's Cost of Revenue over 5 years: stood at $2.1 billion in 2022, then plunged by 71.13% to $610.0 million in 2023, then soared by 980.33% to $6.6 billion in 2024, then slumped by 68.8% to $2.1 billion in 2025, then slumped by 66.15% to $696.0 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $696.0 million, $2.1 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison